scholarly journals Micro RNAs (miRNAs) as potential biomarkers in tuberculosis: A systematic review

Author(s):  
Bijay Pattnaik ◽  
Niharika Patnaik ◽  
Saurabh Mittal ◽  
Anant Mohan ◽  
Anurag Agrawal ◽  
...  
2018 ◽  
Vol 214 (10) ◽  
pp. 1556-1563 ◽  
Author(s):  
Jialin Meng ◽  
Wanzhen Li ◽  
Meng Zhang ◽  
Zongyao Hao ◽  
Song Fan ◽  
...  

PLoS ONE ◽  
2019 ◽  
Vol 14 (4) ◽  
pp. e0214671 ◽  
Author(s):  
Thy Pham Hoai Nguyen ◽  
Cameron James Patrick ◽  
Laura Jean Parry ◽  
Mary Familari

2019 ◽  
Vol 17 (7) ◽  
pp. 630-647 ◽  
Author(s):  
Carmen Peña-Bautista ◽  
Miguel Baquero ◽  
Máximo Vento ◽  
Consuelo Cháfer-Pericás

Background:Alzheimer’s disease (AD), the most common cause of dementia in adulthood, has great medical, social, and economic impact worldwide. Available treatments result in symptomatic relief, and most of them are indicated from the early stages of the disease. Therefore, there is an increasing body of research developing accurate and early diagnoses, as well as diseasemodifying therapies.Objective:Advancing the knowledge of AD physiopathological mechanisms, improving early diagnosis and developing effective treatments from omics-based biomarkers.Methods:Studies using omics technologies to detect early AD, were reviewed with a particular focus on the metabolites/lipids, micro-RNAs and proteins, which are identified as potential biomarkers in non-invasive samples.Results:This review summarizes recent research on metabolomics/lipidomics, epigenomics and proteomics, applied to early AD detection. Main research lines are the study of metabolites from pathways, such as lipid, amino acid and neurotransmitter metabolisms, cholesterol biosynthesis, and Krebs and urea cycles. In addition, some microRNAs and proteins (microglobulins, interleukins), related to a common network with amyloid precursor protein and tau, have been also identified as potential biomarkers. Nevertheless, the reproducibility of results among studies is not good enough and a standard methodological approach is needed in order to obtain accurate information.Conclusion:The assessment of metabolomic/lipidomic, epigenomic and proteomic changes associated with AD to identify early biomarkers in non-invasive samples from well-defined participants groups will potentially allow the advancement in the early diagnosis and improvement of therapeutic interventions.


2021 ◽  
Vol 18 (1) ◽  
pp. 128-136
Author(s):  
Qian Zhou ◽  
Jian Yin ◽  
Yadong Wang ◽  
Xinsuo Zhuang ◽  
Zhiyang He ◽  
...  

2009 ◽  
Vol 89 (6) ◽  
pp. 1953S-1959S ◽  
Author(s):  
Lee Hooper ◽  
Kate Ashton ◽  
Linda J Harvey ◽  
Tamás Decsi ◽  
Susan J Fairweather-Tait

2021 ◽  
Vol 11 ◽  
Author(s):  
Mingfei Wang ◽  
Linfeng Zhang ◽  
Wenhao Ren ◽  
Shaoming Li ◽  
Keqian Zhi ◽  
...  

IntroductionCircular RNAs (CircRNAs), an emerging non-coding RNA, have been demonstrated to be involved in tumorigenesis, metastasis, and cancer progression, and could represent novel potential biomarkers for diagnosing oral squamous cell carcinoma (OSCC). However, no meta-analysis has investigated the diagnostic role of circRNAs in OSCC. Hence, to investigate whether circRNAs could serve as specific biomarkers for OSCC, the present systematic review and meta-analysis evaluated the diagnostic efficiency of circRNAs in patients with OSCC.Materials and MethodsA thorough search of online databases (Pubmed, Web of Science, Embase, and the Cochrane Library) was conducted to collect relevant studies up to March 30th, 2021. All eligible studies were case-control studies. The quality of each study was evaluated by the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. STATA (version 15.1) and Review Manager (version 5.4) were employed to conduct the meta-analysis, and the PRISMA statement was adopted in this study.ResultsA total of 16 studies were included in the meta-analysis, with five studies on upregulated circRNAs, and 11 on downregulated circRNAs. The enrolled studies that met our eligibility criteria all derived from China. The pooled sensitivity (SEN), specificity (SPE), diagnostic odds ratio (DOR), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and the area under receiver operating characteristics curve (AUC) with the 95% confidence intervals (95% CIs) were 0.74 (0.69–0.79), 0.79 (0.73–0.84), 10.74 (7.81–14.77), 3.50 (2.78–4.45), 0.33 (0.27–0.39) and 0.83 (0.79–0.86), respectively. The subgroup analysis demonstrated that serum, plasma, and saliva specimens had a better diagnostic performance than tissue samples, with a high value of sensitivity, specificity, DOR, and AUC values. The results also showed that the subgroups of upregulated circRNAs and a sample size of ≥100 manifested higher specificity, DOR, and AUC for cancer detection than downregulated circRNAs and a sample size of < 100.ConclusionsA strong association was demonstrated between the dysregulated expression of circRNAs and the diagnosis of OSCC. Hence, circRNAs have the potential to function as promising biomarkers and therapeutic targets for OSCC.Systematic Review RegistrationPROSPERO, number CRD42021256857.


Sign in / Sign up

Export Citation Format

Share Document